184 search results for: Clinical Management
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.
ERS-ISIAN 2025 | Disease Control in CRSwNP
Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
2025 ADVENT Forum | Potential for Disease Modification in the Airway
Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.
